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Identity 
Other names: AHO, C20orf45, GNAS1, GPSA, GSA, 
GSP, NESP, PHP1A, PHP1B, PHP1C, POH 
HGNC (Hugo): GNAS 
Location: 20q13.32 
Note 
The gene encoding the Gsα protein gene GNAS 
(Guanine Nucleotide binding protein, Alpha 
Stimulating) is located in one of the most complex 
locus of the human genome, the GNAS locus, on the 
long arm of chromosome 20 (20q13.32) (Gejman et al., 
1991).  
The complexity of this locus does not lie only in the 
four alternative first exons splicing onto common exons 
2 to 13, or the antisense transcript that resides in this 
locus, but this locus also presents an elaborated 
imprinting pattern.  
The genomic imprinting is an epigenetic process in 
which a specific imprint mark is erased in primordial 
germ cells and then reestablished during oogenesis or 
spermatogenesis, resulting in suppression of gene 
expression from one parental allele (Reik and Walter, 
2001).  
This differential gene expression may take whole 
lifetime or just a limited developmental stage, and can 
be generalized to all tissues that express the geneor 
may be tissue dependent (Latham, 1995; Solter, 1998). 
In most cases, the methylation of the allele is the
imprinting mark (addition of methyl  
groups on cytosine in the CpG dinucleotides), but other 
times, the imprinting mechanism remains unknown. 
DNA/RNA 
Description 
The GNAS gene spans over 20-kilobase pair and 
contains thirteen exons and codifies the α-subunit of 
the stimulatory G protein (Gsα) (Kozasa et al., 1988). 
Transcription 
The GNAS locus produces multiple gene products as it
has four alternative first exons (NESP55 (Ischia et l., 
1997), XLαs (Kehlenbach et al., 1994), A/B (Ishikawa 
et al., 1990; Swaroop et al., 1991) and E1-Gsα) that 
splice onto a common exons 2 to 13.  
These first alternative exons lie within CpG islands and 
are differently imprinted, while to increase its 
complexity this locus also has an antisense transcript to 
NESP55, referred as NESPas (Hayward and Bonthron, 
2000) (Figure 1). 
Exon A/B or exon 1A, located 2.5 kb centromeric from 
Gsα exon 1, splices onto common exons 2-13, and is 
methylated on the maternal allele. In this case, because 
there is no consensus AUG translational start site in 
exon A/B, it is thought that the resulting transcript is 
not translated (Ishikawa et al., 1990; Liu et al., 2000). 
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Figure 1. Organization and imprinting of the GNAS complex locus. The general organization and imprinting patterns of the paternal 
(above) and maternal (below) GNAS alleles are shown, with the exons of sense transcripts (NESP55, XL, A/B, and Gαs) depicted as 
black boxes, the common exons 2 to 13 represented as green boxes, the five exons of the antisense transcript (AS) represented as grey 
boxes and the eight exons of the STX16 gene represented as orange boxes. The active sense and antisense promoters (arrows), as well 
as the splicing patterns of their respective paternal (blue) and maternal (pink) transcripts, are shown above and below the paternal and 
maternal exons, respectively. The dotted arrow for the paternal Gαs transcription indicates that the promoter is fully active in most tissues 
but is presumed to be silenced in some tissues, such as renal proximal tubules. Regions that are differentially methylated are 
represented as stars (red, methylated and white, unmethylated). 
 
It has been suggested that this region has a negativ  
regulatory cis-acting element that suppresses the 
paternal Gsα allele in a tissue specific manner (i.e. 
renal proximal tubules) (Williamson et al., 2004; Liu et 
al., 2005). 
XLαs alternative first exon, is located about 35 kb 
centromeric from Gsα exon 1, join exons 2-13 leading 
a transcript that encodes the extra large protein (XLαs), 
an isoform of Gsα with similar functions but slightly 
longer, and its promoter is imprinted on the maternal 
allele (Hayward et al., 1998b). 
Finally, the farthest alternative exon (49kb centromeric 
from exon 1), together with the other common exons 2-
13, makes the transcript encoding the protein NESP55, 
chromogranin-like protein that is expressed mostly in 
neuroendocrine tissues and only from the maternal 
allele, due to methylation on the paternal allele 
(Hayward et al., 1998b). 
Regarding GNAS gene transcripts, by different splicing 
of exon 3 and/or use of two 5'splice sites of exon 4, two 
long (Gsα-L) and two short (Gsα-S) transcript variants 
are created, which contain alternatively exon 3 and/or a 
CAG sequence, respectively (Figure 2) (Bray et al., 
1986; Robishaw et al., 1986; Kozasa et al., 1988). It is 
not methylated on either allele (Kozasa et al., 1988; 
Hayward et al., 1998a; Peters et al., 1999; Liu et al., 
2005). 
Pseudogene 
No pseudogenes have been identified. 
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Figure 2. Gsα protein isoforms. Two long (Gsα-1 and Gsα-2) and two short (Gsα-3 and Gsα-4) forms of Gsα result from alternative 
splicing of exon 3. Use of an alternative splice acceptor site for exon 4 leads to insertion of an extra serine residue in Gsα-2 and Gsα-4. 
Introns are represented as dash lines, exons as orange boxes; UTRs as black boxes, serine residue as blue hexagons and splicing 




The Gsα protein has 394 aminoacids with a mass of 
about 46 kDa. Gα-subunits contain two domains: a 
GTPase domain that is involved in the binding and 
hydrolysis of GTP and a helical domain. 
The α subunit guanine nucleotide pocket consists of 
five distinct, highly conserved stretches (G1-G5). The 
G1, G4 and G5 regions are important for the binding of 
GTP while the G2 and G3 regions determine the 
intrinsic GTPase activity of the α subunit. The GDP-
bound form binds tightly to bg and is inactive, whereas 
the GTP-bound form dissociates from bg and serves as 
a regulator of effector proteins. The receptor molecul s 
cause the activation of G proteins by affecting several 
steps of the GTP cycle, resulting in the facilitation of 
the exchange of GTP for GDP on the α subunit (Lania 
et al., 2001; Cherfils and Chabre, 2003). 
Expression 
GNAS is biallelically expressed in most tissues studied 
(Hayward et al., 1998a; Hayward et al., 1998b; Zheng 
et al., 2001; Mantovani et al., 2004); however, in some 
tissues (thyroid, renal proximal tubule, pituitary and 
ovaries) primarily maternal expression is observed 
leading to a parental-of-origin effect (Davies and 
Hughes, 1993; Campbell et al., 1994; Yu et al., 1998; 
Hayward et al., 2001; Weinstein, 2001; Mantovani et 




Heterotrimeric G proteins are membrane bound 
GTPases that are linked to seven-transmembrane 
domain receptors (Kleuss and Krause, 2003). Each G 
protein contains an alpha-, beta- and gamma-subunit 
and is bound to GDP in the "off" state (Olate and 
Allende, 1991).  
Ligand-receptor binding results in detachment of the G 
protein, switching it to an "on" state and permitting Gα 
activation of second messenger signalling cascades 
(Cabrera-Vera et al., 2003).  
Gsα mediates the simulation of adenylate cyclase 
regulated by various peptide hormones (PTH, TSH, 
gonadotropins, ACTH, GHRH, ADH, glucagon, 
calcitonin, among others) (Spiegel, 1999; Spiegel and
Weinstein, 2004).  
Gsα-subunits contain two domains: a GTPase domain 
that is involved in the binding and hydrolysis of GTP 
and a helical domain that buries the GTP within the 
core of the protein (Cabrera-Vera et al., 2003). 
Exon 5 is thought to codify the highly conserved 
domain of Gsa that interacts with adenylate cyclase, 
while exon 13 is responsible for the interaction with the 
receptor (Pennington, 1994). 
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Figure 3. Schematic representation of GNAS gene and Gsα protein. (A) Schematic scaled representation of the 13 coding exons for 
GNAS gene (Black rectangles represent the exons, grey rectangles the untranslated regions, and the black line the intronic region). (B) 
Schematic representation of Gsα protein, where the blue rectangles represents the 4 different domains located in the protein (exons 1 
and 2 encode for the GTPase activity domain; exons 4 and 5 for the adenylyl cyclase activity domain; exon 9 for the GTP dependent 
conformational change domain; and exons 12 and 13 for the G-protein coupled receptor interaction domain). The figure also shows the 
localization of the activating mutations in exon 8 (R201) and exon 9 (Q227). 
 
Homology 
There are several types of Gα proteins; Gsα, Gqα, 
Gi/oα and G12/13α (Riobo and Manning, 2005). 
Members of Gsα bind directly to adenylyl cyclase and 
stimulate its activity, whereas their effects on ion 
channel activity are restricted to selected cell types; 
Gi/oα are involved in adenylyl cyclase inhibition, ion 
channel modulation and phosphatase activation. 
Finally, G12/13α family is implicated in processes of 
determination and cell proliferation. Subunits of the 
Gq/11 class are putative mediators of phospholipase C 
activation (Landis et al., 1989; Lania et al., 2001). 
Mutations 
Note 
Both germinal and somatic, activating and inactivating, 
genetic and epigenetic alterations have been describ d 
at GNAS locus associated with different entities. 
Activating mutations: Mutations at Arg201 or Gln227 
inhibits the GTPase activity, maintaining Gsα in its 
active form. The mutant Gsα protein carrying these 
activating mutations is termed the gsp oncogene 
(Landis et al., 1989). 
In McCune-Albright syndrome, the somatic mutation at 
Arg201, leading to its change into cysteine or histidine 
(even serine or glycine), occurs in early embryogenesis, 
resulting in widespread tissue distribution of  
abnormalities. The post zygotic mutation is responsible 
for the mosaic pattern of tissue distribution and the
extreme variability of clinical changes (Weinstein et 
al., 1991). 
Endocrine and non-endocrine tumors: Somatic 
mutations of Arg201 or Gln227 have been identified in 
human growth hormone-secreting pituitary adenomas, 
(Landis et al., 1989; Landis et al., 1990), ACTH-
secreting pituitary adenomas (Williamson et al., 1995; 
Riminucci et al., 2002), nonfunctioning pituitary 
tumors (Tordjman et al., 1993), thyroid tumors (Suarez 
et al., 1991), Leydig cell tumor (Libe et al., 2012), 
ovarian granulosa cell tumors (Kalfa et al., 2006a), 
renal cell carcinoma (Kalfa et al., 2006b), 
hepatocellular carcinoma (Nault et al., 2012) and 
myelodysplastic syndromes (Bejar et al., 2011).  
The mutation at codon 201 (Arg into Cys or His) is 
more frequent that the mutation at 227 (Gln into Arg, 
His, Lys or Leu). 
Fibrous dysplasia of the bone: Fibrous dysplasia (FD) 
is a benign intramedullary osteofibrous lesion that m y 
involve either one (monostotic FD) or several 
(polyostotic FD) bones.  
FD may occur in isolation or as part of the McCune-
Albright syndrome or within Mazabraud's syndrome. 
Some cases of FD have been found to have a somatic 
GNAS mutation, mainly R201C and R201H 
(Riminucci et al., 1997), though R201S (Candeliere t 
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al., 1997) and Q227L (Idowu et al., 2007) has also been 
reported. 
Inactivating mutations: The first reports of germ-line 
inactivating Gsα mutations were reported in 1990 
(Patten et al., 1990; Weinstein et al., 1990). Latter on, 
many different mutations have been described in 
literature and summarized in the Human Gene 
Mutation Database at the Institute of Medical Genetics 
in Cardiff (www.hgmd.cf.ac.uk) as a cause of a 
hormonal disorder coupled to Gsα activity 
characterized by PTH renal resistance called 
Pseudohypoparathyroidism (PHP). 
Mutation types include translation initiation mutations, 
amino acid substitutions, nonsense mutations, 
inversions, splice site mutations, insertions or deletions 
(even intragenic or encompassing the whole gene). 
Mutations are distributed throughout the Gsα coding 
region. Although each mutation is usually associated to 
a single kindred, a mutational hot-spot involving 20% 
of all mutations so far described has been identifid 
within exon 7 (Weinstein et al., 1992; Yu et al., 1995; 
Yokoyama et al., 1996; Ahmed et al., 1998; Mantovani 
et al., 2000; Aldred and Trembath, 2000). It is a 4bp 
deletion which coincides with a defined consensus 
sequence for arrest of DNA polymerase a, a region 
known to be prone to sporadic deletion mutations 
(Krawczak and Cooper, 1991; Yu et al., 1995). In most 
cases it has been found as a de novo mutation, thus 
representing a recurring new mutation rather than a 
founder effect. 
As mentioned above, in some tissues paternal GNAS 
allele is silenced, leading to a parental-of-origin effect. 
In case of maternally inherited mutation, AHO is 
associated with end-organ resistance to the Gsα-
mediated action of different hormones, primarily PTH, 
TSH, gonadotropin, and GHRH. AHO with 
endocrinopathy is then termed 
pseudohypoparathyroidism type Ia (PHP-Ia; MIM: 
103580) or pseudohypoparathyroidism type Ic (PHP-Ic; 
MIM: 612462). In contrast, AHO due to paternally 
inherited mutation transmission lacks biochemical 
evidence of hormone resistance and is designated as 
pseudopseudohypoparathyroidism (PPHP; MIM 
612463) (Davies and Hughes, 1993; Campbell et al., 
1994; Weinstein, 2001; Weinstein et al., 2004) (see 
below for further details). 
An intriguing missense mutation (Iiri et al., 1994; 
Nakamoto et al., 1996) localized within the highly 
conserved G5 region of the Gsα, has been identified in 
two unrelated males who presented with AHO, PTH 
resistance and testotoxicosis (Iiri et al., 1994). This 
substitution (A366S) leads to constitutive activation of 
adenylyl cyclase by causing accelerated release of 
GDP, thus increasing the fraction of active GTP-bound 
Gsα. However, while this mutant protein is stable at the
reduced temperature of the testis, it is thermolabile at 
37°C, resulting in reduced Gsα activity in almost 
tissues and AHO phenotype. 
Progressive Osseous Heteroplasia (POH; MIM: 
166350) is defined by cutaneous ossification, 
characteristically presenting during childhood, that 
progresses to involve subcutaneous and deep 
connective tissues, including muscle and fascia, in the 
absence of multiple features of Albright hereditary 
osteodystrophy (AHO) or hormone resistance (Kaplan 
et al., 1994). Most cases of POH are caused by 
heterozygous paternally-inherited inactivating 
mutations of GNAS (Shore et al., 2002; Adegbite et al., 
2008). 
Epigenetic alterations: Loss of methylation at GNAS 
exon A/B, sometimes combined with epigenetic defects 
at other GNAS differentially methylated regions has 
been associated with pseudohypoparathyroidism type 
Ib (PHP-Ib; MIM: 603233). The familial form of the 
disease has been shown to be mostly associated with an 
exon A/B-only methylation defect and a heterozygous 
3-kb or 4.4-kb deletion mutation within the closely 
linked STX16 gene (Bastepe et al., 2003; Linglart et 
al., 2005), although four families of AD-PHP-Ib 
associated with NESP55 and NESPas deletions have 
also been described, the latter leading to the loss of all 
maternal GNAS imprints (Bastepe et al., 2005; 
Chillambhi et al., 2010; Richard et al., 2012). The exon 
A/B region is known as an imprinting control region 
and is believed to be critical for the tissue-specific 
imprinting of Gsα in the renal proximal tubules 
(Weinstein et al., 2001). The sporadic form of PHP-Ib 
show complete loss of methylation at the NESPas, 
XLαs and A/B regions, and no other changes in cis- or 
trans-acting elements have been found to explain this 
loss of methylation. In the scientific literature six cases 
have been described in which there is an association 
between the complete loss of methylation and partial or 
complete paternal isodisomy of chromosome 20q 
covering the GNAS locus (Bastepe et al., 2001; 
Bastepe et al., 2010; Fernandez-Rebollo et al., 2010). 
And on the other hand, it has been recently published a 
new trait of inheritance, an autosomal recessive form, 
explaining the molecular mechanism underlying the 





The McCune-Albright syndrome (MAS) is a rare, 
sporadic disease characterized by a classical triadof 
clinical signs: polyostotic fibrous dysplasia (FD), skin 
hyperpigmentation (cafe-au-lait spots) and endocrine 
dysfunction. The major endocrine disorders include 
autonomous hyperfunction of several endocrine glands, 
such as gonads, thyroid, pituitary and adrenal cortex, 
i.e. glands sensitive to trophic agents acting through 
cAMP dependent pathway. Moreover, increasing data 
drive the attention to non-endocrine affections, 
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including hepatobiliary dysfunction and cardiac 
disease, which are probably important risk factors f  
early death.  
As mutation detection rates may vary considerably 
according to the type of tissue analyzed and the 
detection method used, sensitive and specific molecular 
methods must be used to look for the mutation from all 
available affected tissues and from easily accessible 
tissues, particularly in the presence of atypical and 
monosymptomatic forms of MAS (Weinstein, 2006; 
Chapurlat and Orcel, 2008). 
Prognosis 
The prognosis depends on the severity of each 
individual endocrine and non-endocrine manifestation 
and on the age at which each affection appears.  
Bisphosphonates are used in the treatment of FD to 
relieve bone pain and improve lytic lesions, but they 
are still under clinical evaluation.  
Calcium, vitamin D and phosphorus supplements may 
be useful in some patients.  
Surgery is also helpful to prevent and treat fracture and 
deformities.  
Oncogenesis 
Postzygotic, somatic mutations at Arginine 201 of the
GNAS gene that results in cellular mosaicism, thus 
leading to a broad spectrum of clinical manifestations. 
Mazabraud syndrome 
Note 
Very rare association of fibrous dysplasia and 
myxomas of the soft tissues (Biagini et al., 1987; 
Dreizin et al., 2012). 
Various endocrine and non-endocrine 
tumors 
Note 
Growth hormone-secreting pituitary adenomas (Landis 
et al., 1989; Landis et al., 1990), ACTH-secreting 
pituitary adenomas (Williamson et al., 1995; Riminucci 
et al., 2002), nonfunctioning pituitary tumors 
(Tordjman et al., 1993), thyroid tumors (Suarez et al., 
1991), Leydig cell tumor (Libe et al., 2012), ovarian 
granulosa cell tumors (Kalfa et al., 2006a), ACTH-
independent macronodular adrenal hyperplasia 
(AIMAH) (Fragoso et al., 2003), renal cell carcinoma 
(Kalfa et al., 2006b), hepatocellular carcinoma (Nault 
et al., 2012) and myelodysplastic syndromes (Bejar t 
al., 2011).  
Activating GNAS mutations are a common feature of 
the above-mentioned endocrine tumors with a 
maximum frequency in growth hormone-secreting 
pituitary adenomas (about 30-40%) (Landis et al., 
1989), while the same mutations have been only 
occasionally reported in the other cited tumors. 
Oncogenesis 
Activating mutations of the α subunit of the stimulatory 
G protein (Gsα) gene (the gsp oncogene) leading to 
amino acid substitution of either residue Arg201 or 
Gln227.  
These two residues are catalytically important for 
GTPase activity, their mutation thus causing 
constitutive activation by disrupting the signalling turn-
off mechanism.  
Growth and hormone release in many endocrine glands 
are stimulated by trophic hormones that activate Gsα-
cAMP pathways, therefore GNAS activating mutations 
affect those glands sensitive to trophic agents acting 
through the cAMP-dependent pathway, leading to 




Pseudohypoparathyroidism (PHP) is a term applied to a 
heterogeneous group of disorders whose common 
feature is end-organ resistance to parathyroid hormone 
(PTH) (Mantovani, 2011). 
PTH resistance, the most clinically evident 
abnormality, usually develops over the first years of 
life, with hyperphosphatemia and elevated PTH 
generally preceding hypocalcemia. Renal function is 
conserved through life and so seems to be bone mineral 
density. 
Diagnostic Criteria for PHP: 
- elevated PTH levels 
- hypocalcemia 
- hyperphosphatemia 
- absence of hypercalciuria or impaired renal functio  
- reduced calcemic and phosphaturic response to 
injected exogenous PTH. 
Disease 
PHP-Ia: in addition to PTH resistance, is characterized 
by resistance to other hormones, including TSH, 
gonadotrophins and GHRH. It is associated with 
Albright's hereditary osteodystrophy (AHO), which 
includes short stature, obesity, round facies, 
subcutaneous ossifications, brachydactyly, and other 
skeletal anomalies.  
Some patients have mental retardation.  
Laboratory studies show a decreased cAMP response t 
infused PTH and defects in activity of the erythrocyte 
Gs protein (Mantovani, 2011). 
Pseudo-PHP (PPHP): is characterized by the physical 
findings of AHO without hormone resistance. 
Laboratory studies show a defect in Gs protein activity 
in erythrocytes (Weinstein et al., 2001). 
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Table1. Legend: PHP, pseudohypoparathyroidism; PPHP, Pseudo-pseudohypoparathyroidism; AHO, Albright hereditary 
osteodystrophy; POH, Progressive Osseous Heteroplasia; Gn, gonadotropins; NA, not available. 
 
PHP-Ib:  is characterized clinically by isolated renal 
PTH resistance.  
Patients usually lack the physical characteristics of 
AHO and typically show no other endocrine 
abnormalities, although resistance to TSH has been 
reported. 
However, patients may rarely show some features of 
AHO. Laboratory studies show a decreased cAMP 
response to infused PTH and, most recently reported, 
sometimes defects in Gs protein activity similarly to 
PHP-Ia patients (Zazo et al., 2011; Mantovani et al., 
2012). 
PHP-Ic: is clinically indistinguishable from PHP-Ia, 
therefore being characterized by the association of 
multi-hormone resistance and AHO. Laboratory studies 
show a decreased cAMP response to infused PTH, but 
typically no defect in activity of the erythrocyte Gs 
protein (Thiele et al., 2011). 
Progressive Osseous Heteroplasia (POH): is 
characterized by ectopic dermal ossification beginning 
in infancy, followed by increasing and extensive bone 
formation in deep muscle and fascia. These patients 
typically do not show any endocrine abnormality 
(Shore et al., 2002; Shore and Kaplan, 2010). 
Prognosis 
In general, PHP patients should be monitored annually 
for both blood biochemistries (PTH, calcium, 
phosphate, TSH) and urinary calcium excretion. 
Particular attention must be given in children to heig t, 
growth velocity and pubertal development. Increasing 
evidences suggest that, independently of growth curve, 
children should be screened with appropriate 
provocative tests for GH deficiency in order to 
eventually start treatment as soon as possible. Weight 
and BMI should be checked in order to start 
dietary/exercise intervention when appropriate. Careful 
physical examination and, when necessary, specific 
psychological investigations should be performed 
annually in order to detect and follow the 
presence/evolution of specific AHO features (in 
particular heterotopic ossifications and mental 
retardation). Initial screening should include 
radiological evaluation of brachydactyly. 
The long-term therapy of hypocalcemia, in order to 
maintain normocalcemia, is with active vitamin D 
metabolites, preferentially calcitriol, with or without 
oral calcium supplementation.  
Patients should be also routinely screened and 
eventually treated for any associated endocrinopathy, in 
particular hypothyroidism and hypogonadism.  
Levothyroxine and sex hormones should be given 
following the same criteria, doses and follow-up as in 
any other form of hypothyroidism or hypogonadism. 
There are no specific treatments for the various 
manifestations of AHO, even if subcutaneous 
ossifications may be surgically removed when 
particularly large or bothersome. 
While prognosis of correctly treated hormone 
disturbances is very good, POH may end up with 
deeply invalidating lesions. 
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